BridgeBio to Participate in September Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced its participation in three major healthcare investor conferences in September 2025. The management team will host fireside chats at the Wells Fargo Healthcare Conference in Boston (September 3), the Cantor Global Healthcare Conference in New York (September 4), and the Morgan Stanley Global Healthcare Conference in New York (September 8).
Investors can access live webcasts of the presentations through BridgeBio's investor relations website, with replays available for 90 days following each event.
Details
News Market Reaction – BBIO
On Aug 27, the day this news came out, BBIO closed 1.47% above the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:
- Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ET
- Cantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at 2:10 pm ET
- Morgan Stanley Global Healthcare Conference – New York, NY: Fireside chat on Monday, September 8 at 3:20 pm ET
To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.